Acute myeloid leukemia (AML) is a leading cause of cancer-related deaths in young adults and a highly lethal disease in older adults. Most AML patients do not survive longer than two years.

The Leucegene project will help pave the way for a new era in personalized medicine and offer patients better targeted therapies. We envision higher cure rates and longer, disease-free lifespans for AML patients.


Listen to Guy Sauvageau’s interview at the ESH 5th International Conference on AML

Click on Guy Sauvageau's interview last october on why should…

Vincent Lavallée’s Laboratory is joining the Leucegene group!

Vincent will bring his expertise in single cell sequencing analysis!…



Next-generation sequencing, chemogenomic and precision medicine approaches to cure AML

Health Care Providers

Driving new prognostic tests to the clinic through socio-economic studies and clinician engagement


Delivering precision medicine for AML to provide cures for this disease

Our Partners